Used in neuroscience and clinical research to quantify phencyclidine (PCP) receptor activity in human biological samples such as serum, plasma, or cerebrospinal fluid. Enables assessment of PCP binding levels in studies related to NMDA receptor dysfunction, schizophrenia, and other psychiatric disorders. Supports drug development and toxicology screening by providing a reliable method to measure PCP-like compounds' effects on receptor activity. Commonly applied in biomarker validation and therapeutic monitoring where glutamatergic signaling is implicated.